Commitments and Contingencies - Narrative (Details) - Drug Substance Agreement - USD ($) |
12 Months Ended | |
|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Purchase Commitment, Excluding Long-Term Commitment [Line Items] | ||
| Additional costs related to clinical studies | $ 2,150,000 | |
| Remaining amounts committed | 2,614,000 | |
| Costs related to clinical studies | $ 0 | $ 200,000 |
| X | ||||||||||
- Definition Amount of additional research and development expenses incurred for clinical studies of drug substance manufacturing under CRO Agreements. No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|